Excessive Daytime Sleepiness Market Forecast

DelveInsight’s Excessive Daytime Sleepiness Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, June 4, 2024 /EINPresswire.com/ --
DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Excessive Daytime Sleepiness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Excessive Daytime Sleepiness Market Forecast

Some of the key facts of the Excessive Daytime Sleepiness Market Report:
The Excessive Daytime Sleepiness market size was valued approximately USD 4,946 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
Parkinson's disease (PD), narcolepsy, idiopathic hypersomnia (IH), obstructive sleep apnea (OSA), and bipolar disorder (BD) are some of the key conditions in which Excessive Daytime Sleepiness occurs
In 2021, it was predicted that 6,857,997 people in the 7MM would have Excessive Daytime Sleepiness that had been identified as widespread
The predicted number of Americans with diagnosed prevalent cases of Excessive Daytime Sleepiness in 2021 was 3,736,749
The emerging pipeline for Excessive Daytime Sleepiness (EDS) includes Avadel Pharmaceuticals' FT218, a once-nightly sodium oxybate formulation that has received tentative approval for treating EDS and cataplexy in adults with narcolepsy, as well as Axsome Therapeutics' AXS-12 (reboxetine) and several other potential products in development.
Key Excessive Daytime Sleepiness Companies: Suven LifeSciences, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, NLS Pharma, XWPharma, Takeda, and others
Key Excessive Daytime Sleepiness Therapies: SUVN-G3031, FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others
The Excessive Daytime Sleepiness epidemiology based diagnosed prevalent cases analyzed that in the US, the majority of the cases of EDS are found in OSA and Bipolar disorder, followed by Parkinson's Disease, Narcolepsy, and Idiopathic Hypersomnia
The Excessive Daytime Sleepiness market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Excessive Daytime Sleepiness pipeline products will significantly revolutionize the Excessive Daytime Sleepiness market dynamics.

Excessive Daytime Sleepiness Overview
Excessive Daytime Sleepiness (EDS) is a condition characterized by an overwhelming urge to sleep or a general feeling of drowsiness during the day. It goes beyond typical tiredness and can interfere with daily activities, affecting concentration, mood, and overall functioning. EDS is often a symptom of various underlying conditions rather than a standalone diagnosis.

Get a Free sample for the Excessive Daytime Sleepiness Market Report:
https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Excessive Daytime Sleepiness Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Excessive Daytime Sleepiness Epidemiology Segmentation:
The Excessive Daytime Sleepiness market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Excessive Daytime Sleepiness
Prevalent Cases of Excessive Daytime Sleepiness by severity
Gender-specific Prevalence of Excessive Daytime Sleepiness
Diagnosed Cases of Episodic and Chronic Excessive Daytime Sleepiness

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiology Forecast

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Excessive Daytime Sleepiness Therapies and Key Companies
SUVN-G3031: Suven LifeSciences
FT218: Avadel Pharmaceutical
AXS-12: Axsome Therapeutic
THN102: Theranexus
Samelisant: Suven Life Sciences
Quilience: NLS Pharma
XW10172: XWPharma
TAK-994: Takeda

Excessive Daytime Sleepiness Market Drivers
Robust clinical pipeline
Support of the US FDA by granting designations
Recent launch of Xywav and Ozawade
Increasing prevalence dueto appearance of EDS as asymptom in various disorders

Excessive Daytime Sleepiness Market Barriers
High cost of therapies
Delay in diagnosis
A limited number of participants
Lack of practical measurement tools in diagnosis

Scope of the Excessive Daytime Sleepiness Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Excessive Daytime Sleepiness Companies: Suven LifeSciences, Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, NLS Pharma, XWPharma, Takeda, and others
Key Excessive Daytime Sleepiness Therapies: SUVN-G3031, FT218, AXS-12, THN102, Samelisant, Quilience, XW10172, TAK-994, and others
Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies
Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Excessive Daytime Sleepiness Unmet Needs, KOL’s views, Analyst’s views, Excessive Daytime Sleepiness Market Access and Reimbursement

To know more about Excessive Daytime Sleepiness companies working in the treatment market, visit @ Excessive Daytime Sleepiness Clinical Trials and Therapeutic Assessment

Table of Contents
1. Excessive Daytime Sleepiness Market Report Introduction
2. Executive Summary for Excessive Daytime Sleepiness
3. SWOT analysis of Excessive Daytime Sleepiness
4. Excessive Daytime Sleepiness Patient Share (%) Overview at a Glance
5. Excessive Daytime Sleepiness Market Overview at a Glance
6. Excessive Daytime Sleepiness Disease Background and Overview
7. Excessive Daytime Sleepiness Epidemiology and Patient Population
8. Country-Specific Patient Population of Excessive Daytime Sleepiness
9. Excessive Daytime Sleepiness Current Treatment and Medical Practices
10. Excessive Daytime Sleepiness Unmet Needs
11. Excessive Daytime Sleepiness Emerging Therapies
12. Excessive Daytime Sleepiness Market Outlook
13. Country-Wise Excessive Daytime Sleepiness Market Analysis (2019–2032)
14. Excessive Daytime Sleepiness Market Access and Reimbursement of Therapies
15. Excessive Daytime Sleepiness Market Drivers
16. Excessive Daytime Sleepiness Market Barriers
17. Excessive Daytime Sleepiness Appendix
18. Excessive Daytime Sleepiness Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.